Trial · NCT07907354
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
NCT07907354, Phase 2, Not yet recruiting, Yunnan Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer. Trials, record NCT07907354. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907354
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
- NCT number
- NCT07907354
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 56 participants, estimated
- Lead sponsor
- Yunnan Cancer Hospital
- Conditions
- Breast Neoplasms, Advanced Breast Cancer, HER2-positive Breast Cancer, HER2-low Breast Cancer
- Interventions
- Apatinib mesylate, Physician's choice chemotherapy
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | every 2 cycles (each cycle is 21 or 28 days depending on chosen chemotherapy)， up to disease progression or 24 months | ORR is defined as the proportion of participants with a Complete Response (CR) or Partial Response (PR) as assessed by the investigator according to RECIST v1.1. Response confirmation is not required. |
| Secondary | Progression-Free Survival | From treatment initiation to disease progression or death, assessed every 2 cycles(each cycle is 21 or 28 days depending on chosen chemotherapy) | PFS is defined as the time from treatment initiation to the date of first documented disease progression (per RECIST v1.1) or death from any cause, whichever occurs first. |
| Secondary | Time to Progression (TTP) | From treatment initiation to first progression, assessed every 2 cycles ( each cycle is 21 or 28 days depending on chosen chemotherapy), up to approximately 24 months | Time from first dose to first documented disease progression. |
| Secondary | Overall Survival (OS) | From treatment initiation to death from any cause (up to 36 months) | OS is defined as the time from treatment initiation to the date of death from any cause. Participants alive at last follow-up will be censored. |
| Secondary | Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | Baseline through end of treatment and 30-day follow-up (each cycle is 21 or 28 days depending on chosen chemotherapy) | Safety will be assessed by the incidence, nature, and severity of adverse events (AEs) and serious adverse events (SAEs). AEs will be graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory abnormalities, vital signs, and ECG changes will also be evaluated. |
| Secondary | Clinical Benefit Rate (CBR) | Every 2 cycles（each cycle is 21 or 28 days depending on chosen chemotherapy） up to 24 months | Proportion of patients achieving CR, PR, or stable disease (SD) lasting ≥ 6 months as per RECIST 1.1. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907354
GET https://conductscience.org/api/trials/v1/NCT07907354/registered